Post hematopoietic stem cell transplantation: cost analysis of infections in the first year post-transplant
DOI:
https://doi.org/10.21527/2176-7114.2024.48.13992Keywords:
Hematopoietic Stem Cell Transplantation, Infections, Costs and Cost AnalysisAbstract
Objectives: To analyze the costs of infections in the first year after hematopoietic stem cell transplantation. Methods: analytical cross-sectional studies developed using data from 71 medical records of patients who were diagnosed with hematological cancer and were selected for hematopoietic stem cell transplantation with up to one year of transplantation, with 43 autologous transplants, 20 allogeneic related, 4 allogeneic non-apparent transplants and 4 haploidentical patients who were 18 years of age or older in hematopoietic stem cell transplantation in 2018. Descriptive and correlation analyzes were performed between the variables.
Results: Of the 71 patients, 36 had infections. The highest average expenditure was for haploidentical types (44% versus 9%, p<0.001) and with regard to the underlying disease, the group that had infections had a higher frequency of leukemias (42% versus 14%, p=0.012) . Parameters related to poor prognosis, such as three or more hospitalizations (22% versus 3%, p=0.04), longer hospital stay (22.5 [AIQ= 21 – 55] versus 19 [AIQ=16 – 23 ] days, p<0.001) and higher frequency of death (42% of these 14%, p=0.01), were related to the presence of infection. The group that has infections had a high median compared to the group that did not have infections (5,5519.8 (25,618.8 – 73,806.6) versus 23,872.5 (23,657.7 – 24,927.6) real , p<0.001).
Conclusions: Infections represent one of the main obstacles in the success of transplants, with a high number of patients who died and who developed complications, burdening costs with hospitalizations and procedures, sobrecargar los costos con hospitalizaciones y procedimientos.
References
Batista JL, Birmann BM, Epstein MM. Epidemiology of Hematologic Malignancies. In: Loda M, Mucci L, Mittelstadt M, Van Hemelrijck M, Cotter M, eds. Pathology and Epidemiology of Cancer. Springer, Cham, 2017. [access 17 Feb. 2022]. DOI: https://doi.org/10.1007/978-3-319-35153-7_29
Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2017;18(Supplement 1):i3-i8. [access 21 Jan. 2022]. Disponível em: 10.1093/annonc/mdl443
Instituto Nacional de Câncer José Alencar Gomes da Silva (Inca). Estimativa Câncer Brasil – 2020. Rio de Janeiro: Inca; 2020. [acesso em 15 jan. 2022]. Disponível em: https://www.inca.gov.br/estimativa/introducao. Acesso em: 1º abr. 2020.
Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer; 2019. [access 17 Feb. 2022]. Disponível em: 10.1007/978-3-030-02278-5
Ministério da Saúde (BR). Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA). Estimativa 2016: Incidência de Câncer no Brasil. [internet]. Rio de Janeiro, RJ; 2016. [acesso em 16 november 2020]. Disponível em: http://inca.gov.br/bvscontrolecancer/publicações/edicao_2016.pdf
Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A. Hematopoietic Stem Cell Transplantation. A Global Perspective JAMA. 2010; 303(16):1.617-1.624. [access 22 Nov. 2021]. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/185756
Schuster AL, Bassani BFB, Farias ER. Epidemiologia dos Transplantes de Medula Óssea entre 2010 e 2019 no Brasil. Elsevier, 2021. Hematology, Transfusion and Cell Therapy. 43(Supplement 1):258. [access 2 Nov. 2021]. DOI: https://doi.org/10.1016/j.htct.2021.10.437
Ministério da Educação (BR). EBSERH, Empresa Brasileira de Serviços Hospitalares. Hospital Universitário e Hemoce já realizaram mais de 600 transplantes de medula óssea. 2021. Acesso 10 out. 2021. Disponível em: https://www.gov.br/ebserh/pt-br/hospitais-universitarios/regiao-nordeste/ch-ufc/comunicacao/noticias/hospital-universitario-walter-cantidio-e-hemoce-ja-realizaram-mais-de-600-transplantes-de-medula-ossea
Ministério da Saúde (BR). Ampliação da idade máxima para 75 anos nos procedimentos de Transplante de Células-Tronco Hematopoéticas (TCTH) alogênico. 2020. [Acesso 11 fev. 2022]. Disponível em: http://conitec.gov.br/ultimas-noticias-3/sus-amplia-idade-para-realizacao-de-transplante-de-celulas-tronco-para-doencas-sanguineas-em-idosos#:~:text=O%20Minist%C3%A9rio%20da%20Sa%C3%BAde%20decidiu,de%2060%20para%2075%20anos
Marques ACB, Szczepanik AP, Machado CAM, Santos PND, Guimarães PRB, Kalinke LP. Hematopoietic stem cell transplantation and quality of life during the first year of treatment. Rev. Latino-Am. Enfermagem. 2018 May.;30(65):90-101. [access 16 Nov. 2021]. DOI: https://doi.org/10.1590/1518-8345.2474.3065
Schelfhout J, Brown H, Raval JAH. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant, Current Medical Research and Opinion. 2020;36(1):43-50.
Ueno R, Nishimura S, Fujimoto G, Piao Y, Takenaka K. O fardo clínico e econômico de alogênico gestão pós citomegalovírus hematopoiéticas estaminais célula transplante no Japão – um estudo do banco de dados retrospectiva. Curr Med Res Opin. 2019; 35(12):2.089-2.096.
Marques LF, Barbosa SSM, Schutz V, Silva RCL. Custo-minimização do transplante alogênico de células-tronco com a implementação da sistematização da assistência de enfermagem. Rev enferm UFPE on-line. jul. 2018;12(7):1.923-1.930. [acesso em: 22 nov. 2021]. Disponível em: https://periodicos.ufpe.br/revistas/revistaenf
Hertl, M. Transplante de células-tronco Hematopoiéticas. Manual MSD versão para profissionais de Saúde. Versão em Português, última modificação do conteúdo agosto de 2018. [acesso em: 22 out. 2020]. Disponível em: https://www.msdmanuals.com/pt/profissional/imunologia-dist%C3%BArbios-al%C3%A9rgicos/transplante/transplante-de-c%C3%A9lulas-troncohematopoi%C3%A9ticas
Rodrigues HF, Garbin LM, Castanhol LEC, Simões BP, Curcioli ACJV, Silveira RCCP. Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de enfermagem. Rev Enferm UERJ. 2015 mai-jun; 23(3):304-09. [acesso em: 22 novembro 2021]. DOI: http://dx.doi.org/10.12957/reuerj.2015.4995
Braga M, Cardoso AL, Schio B, Leal FZ, Mielke J, Mozzaquatro JO et al. Avaliação da qualidade de vida de pacientes submetidos ao transplante de células-tronco hematopoéticas. Saúde Santa Maria. abr. 2017;43(1):233-243. [acesso em: 22 nov. 2021]. DOI: https://doi.org/10.5902/2236583425762
Kenzik K, Huang IC, Rizzo JD, Shenkman E, Wingard J. Relationships among symptoms, psychosocial factors, and health-related quality of life in hematopoietic stem cell transplant survivors. Support Care Center. 2015 May 23(3):797-807. [access 15 Nov. 2021]. Disponível em: 10.1007/s00520-014-2420-z. Epub 2014 Sep 6
Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Volin L et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. The Lancet: Haematogy. 2011 jun;4(6):293. [access 22 June 2021]. Disponível em: 10.1016/S2352-3026(17)30081-9
Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohamad M. Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia in Complete Remissio – A Review from The Acute Leukemia Working Party of the EBMT. Haematologica. 2019 May.;100(7):859-869. [access 22 Apr. 2021]. Disponível em: 10.3324/haematol.2015.123331
Braga M, Cardoso AL, Schio B, Leal FZ, Mielke J, Mozzaquatro JO, et al. Avaliação da qualidade de vida de pacientes submetidos ao transplante de células-tronco hematopoéticas. Saúde Santa Maria. abr. 2017;43(1):233-243. [acesso em: 22 jun. 2021]. DOI: https://doi.org/10.5902/2236583425762
Maia SS, Silva JAG, Vasconcelos AM. Transplante de medula óssea e lógica invertida do sus: desafios para a prática do profissional. Revista inclusiones. abr./jun. 2021;8(n. Especial):1-31. [acesso em 17 out. 2020]. Disponível em: 10.1007/s00520-014-2420-z
Sociedade Brasileira de Transplante de Medula Óssea. SBTMO. Centros de transplantes de medula óssea. 2020. [acesso em 22 jun. 2020]. Disponível em: https://sbtmo.org.br/centro-tmo
Ministério da Saúde (MS). Portaria Nº 931 de 2 de maio de 2006. Aprova o Regulamento Técnico para Transplante de Células-Tronco Hematopoéticas. [acesso em: 2 out. 2021]. Disponível em: http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2006/GM/GM-931.htm
Ministério da Saúde (MS). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Diretriz Metodológica: Estudos de Microcusteio Aplicados a Avaliações Econômicas em Saúde. Brasília: Ministério da Saúde, 2019. [acessed 17 fevereiro 2021]. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1005738
Mayerhoff L, Lehne M, Hickstein L, Salimullah T, Prieur S, Thomas SK et al. Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany. J Comp Eff Res. 2019 Jan;8(2):121-131. [access 22 Nov. 2020]. Disponível em: 10.2217/cer-2018-0100
Webb BJ, Harrington R, Schwartz J, Kammerer J, Spalding J, Lee E, et al. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation. Transpl Infect Dis. 2018;20(5):12.961-12.976. [access 22 June 2020]. Disponível em: 10.1111/tid.12961
Robin C, Hémery F, Dindorf C, Thillard J, Cabanne L, Redjoul R, et al. Economic burden of preventive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect Dis. 2017;17(1):747-761. [access 5 Feb. 2020]. Disponível em: 10.1186/s12879-017-2854-2
Latour RP, Chevallier P, Blaise D, Alami S, Bachelot LL, Allavoine T, Tadmouri A, Blomkvist J, Duhamel A, Srour M, Beauvais D, Yakoub-Agha I. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. J Med Virol.2020;12 (16):34-43.
Majhail NS, Rizzo JD, Hahn T, Lee SJ, McCarthy PL, Ammi M, et al. Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013 Jun;48(6):865-71. [access 15 Mar. 2021]. Disponível em: 10.1038/bmt.2012.248.
Alois G, Anna S, Helen B, Michael G, Peter D, Nicolaus K, et al. Economics and Outcome After Hematopoietic StemCell Transplantation: A Retrospective Cohort Study. EBioMedicine. 2(2015)2.101-2.109. [access 25 Mar. 2021. DOI: http://dx.doi.org/10.1016/j.ebiom.2015.11.0212352-3964/©
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista Contexto & Saúde
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
